IL5 and hypereosinophilic syndrome: Although the rationale for use in patients with L-HES is strong given the proven role played by IL-5 in eosinophilic expansion in this variant, we report a disappointing response to anti-IL-5 treatment in our series that is not well reflected by the broad criteria generally used to define a treatment response.